Akrikhin’s Aquadetrim has been given recognition by Russian Pharma Awards®, an annual award for excellence in medicine and pharmacy, as the best brand in the Prevention and Treatment of Rickets in Babies from Birth to 1 Year of Age. The winners were chosen by direct voting of medical practitioners at Doctor At Work, Russia’s largest professional MedTech platform.
Raising awareness of the common problem of insufficiency of vitamin D and its importance for an adult and a child is one of the major items on Akrikhin’s agenda. It is a scientifically proven fact that vitamin D facilitates normal development of bones, reduces the risk of rickets and contributes to the development of many body systems during an active stage of children’s growth. It was Aquadetrim which supported the RODNICHOK All-Russian Pharmacoepidemiological Research Project as a partner in 2012-2017 to study vitamin D levels in children aged 0-3. The research found that only one in three children had normal vitamin D levels in blood. Moreover, in 2020 Akrikhin conducted extensive epidemiological research in Russia to study vitamin D levels in adults, which showed that 84 % of Russian residents had vitamin D insufficiency or deficiency, and this condition even occurred in those who lived in southern regions. For educational purposes, the company launched D-ficitu.net to offer up-to-date and useful information about the important role and health effects of vitamin D.
Aquadetrim has been announced the winner in the Prevention and Treatment of Rickets in Babies from Birth to 1 Year of Age. This is the ninth time that Russian Pharma Awards® take place. Every year the event offers around 20 nominations to 70+ drugs from various pharmaceutical companies. Over 430,000 doctors from all over the country are invited to vote, and a survey covering such a large sample of healthcare professionals demonstrates objective results. The event is a great opportunity to learn the professional medical opinion about specific drugs, and the answers received help to build an adequate MCM strategy. According to a poll at Doctor At Work, 53.9 % of doctors prefer the award-winning brands in writing drug prescriptions.
«Akrikhin» has always been focused on the highest standard and ambitious goals, and we expect trust from doctors and patients. With this award, we have received recognition from an exacting audience like doctors. It is extremely important for any pharmaceutical company to building dialogue with the medical community. Through our participation in Russian Pharma Awards®, we are not only able to demonstrate our long-term performance results, but also support further communication with doctors,
– commented Alexey Maltsev, VP Sales/Marketing, OTC, Akrikhin.
1National Campaign “Vitamin D Insufficiency in Children and Adolescents of the Russian Federation: Advanced Correction Approaches”. Moscow, 2018.// The Union of Paediatricians of Russia. The National Medical Research Center for Children’s Health of the Russian Ministry of Healthcare. The Russian Medical Academy of Continuous Professional Education of the Russian Ministry of Healthcare. The Federal Research Center for Nutrition, Biotechnology and Food Safety.